PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026ANNALS OF ABBASI SHAHEED HOSPITAL AND KARACHI MEDICAL & DENTAL COLLEGEOpen Access

Immune Checkpoint Inhibitor–Induced Seronegative Myasthenia-Like Syndrome Following Pembrolizumab Therapy: A Novel Adverse Drug Reaction

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKhadija ShakoorMHMuhammad Hammad

Discussion

Loading...

Member takes

Overview

A case report reveals seronegative myasthenia-like syndrome in a melanoma patient, highlighting diagnosis and treatment issues.

Key Points

  • To report a case of seronegative myasthenia-like syndrome induced by pembrolizumab therapy.
  • Described the clinical presentation and diagnostic process of the patient.
  • Conducted serological tests for acetylcholine receptor and MuSK antibodies.
  • Performed electrophysiological testing to assess nerve transmission.
  • Administered high-dose steroids and intravenous immunoglobulin as treatment.
  • Patient showed acute bulbar symptoms, ptosis, and generalized fatigability post-treatment.
  • Serological tests returned negative for specific antibodies.
  • Electrophysiological testing indicated a significant postsynaptic transmission defect.
  • Rapid clinical improvement occurred after discontinuation of pembrolizumab and initiation of treatment.

Cite This Study

Shakoor et al. (2026) studied this question.

synapsesocial.com/papers/69a91d21d6127c7a504bfe24https://doi.org/10.58397/hvgap241
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pembrolizumab-Induced Myasthenia Gravis With Myocarditis in the Setting of Metastatic Renal Cell Carcinoma2024
  2. 2C49-24 Pembrolizumab Induced Myasthenia Gravis2026
  3. 3Pembrolizumab-induced fulminant triple M syndrome presenting with severe bradycardia2025 · 2 citations
  4. 4Myositis-Myasthenia Overlap Syndrome After Immune Checkpoint Inhibitor Treatment: A Case Report2026
  5. 5NCMP-24. Bulbar Myasthenic Syndrome in a 65 year-old Woman with Melanoma during treatment with Pembrolizumab: Case Report2025